Dr Reddys Laboratories (RDY) EBIT Margin (2009 - 2023)

Dr Reddys Laboratories (RDY) posted quarterly EBIT Margin of 25.97% for Q2 2023, down 0.67% quarter-over-quarter from 26.14% in Q1 2023.

Dr Reddys Laboratories (RDY) EBIT Margin (2009 - 2023) Analysis & Trends

Dr Reddys Laboratories' EBIT Margin history runs 15 years deep, the most recent figure standing at 25.97% for Q2 2023.

In Q2 2023, EBIT Margin changed N/A year-over-year to 25.97%; the TTM figure through Jun 2023 stood at 24.27% (changed N/A YoY), while the FY2026 annual figure was 15.06%, down 704.0% from the prior year.
EBIT Margin for Q2 2023 stood at 25.97%, down from 26.14% in the prior quarter.
The five-year high for EBIT Margin was 26.14% in Q1 2023, with the low at 13.36% in Q3 2019.
The 5-year median for EBIT Margin is 18.99% (2020), against an average of 14.7%.
Peak annual rise in EBIT Margin reached 772 bps in 2019, while the deepest fall reached 2826 bps in 2019.
Dr Reddys Laboratories' EBIT Margin stood at 13.36% in 2019, then gained by 11 bps to 11.85% in 2020, then soared by 277 bps to 20.98% in 2021, then dropped by 6 bps to 19.69% in 2022, then soared by 32 bps to 25.97% in 2023.
Business Quant data shows RDY's EBIT Margin at 25.97% in Q2 2023, 26.14% in Q1 2023, and 19.69% in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Haleon	43.65 Bn	42.68 Bn	-	-
2	Teva Pharmaceutical Industries	43.09 Bn	39.44 Bn	2.15 Bn	-5.58%
3	Zoetis	31.54 Bn	29.86 Bn	1.05 Bn	33.91%
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn	16.51%
5	United Therapeutics	22.11 Bn	19.45 Bn	683.80 Mn	42.23%
6	Viatris	18.77 Bn	17.88 Bn	1.46 Bn	0.17%
7	Neurocrine Biosciences	15.62 Bn	15.23 Bn	935.80 Mn	15.80%
8	Elanco Animal Health	12.07 Bn	11.54 Bn	798.00 Mn	18.13%
9	Dr Reddys Laboratories	10.09 Bn	9.93 Bn	-	-
10	Alkermes	8.20 Bn	7.54 Bn	397.90 Mn	3.70%

Download Data